ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase 3 studies
AD is the most common chronic inflammatory skin disease in the developed world
Orismilast is a next generation PDE4 inhibitor shown to be potent in inhibiting pathways important in AD
Orismilast MR tablet is also in development for the treatment of psoriasis and hidradenitis suppurativa (HS)
HELLERUP, Denmark, Aug.
